Clinical Trial Update: Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN) [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetic study of liposomal amphotericin B (AmBisome) after a single IV dose in morbidly obese patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity

Drugs mentioned

• Liposomal amphotericin B (amphotericin B liposomal)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Morbid Obesity | Phase 4 | Status: COMPLETED